INTRODUCTION

Wilson’s disease (WD), also known as hepatolenticular degeneration was first described in 1912 by Kinnear Wilson as progressive lenticular degeneration. WD is an inherited, fatal neurological disorder accompanied by chronic liver disease leading to cirrhosis and accumulation of copper in the liver and brain because of defective biliary excretion. Wilson’s disease is due to mutations of the ATP7B gene on chromosome 13.

Case Report

A 14 year old male presented with complaints of difficulty in speaking from last 3-months, dystonia from last 4 days, abnormal posture of lower limbs & tongue from last 3 months. Past history: The patients past history as narrated by his mother is as follows: He was alright till approximately last 3 months when he had an episode of fever and received medication by a private practitioner. The fever subsided after medication, but patient had developed loose stools, difficulty in speaking and pronouncing linguals. With these complaints he was admitted in the hospital. On Radio imaging and ophthalmic examination he was diagnosed as a case of Wilson’s disease and was started with tablet calcium Pantothenate and tablets D-Penicillamine and was discharged. After few days patient was again admitted in the hospital with a chief complaint of abnormal behaviour and increased dystonia which progressed to involve whole left lower limb, right foot, tongue and right upper limb. At that time he was advised to withhold DISTAMINE tablet. He was not relieved of dystonic symptoms though the behavioural symptoms decreased.

ABSTRACT

Wilson’s disease is an autosomal-recessive disorder of copper metabolism resulting from the absence or dysfunction of a copper-transporting protein. The disease is mainly seen in children, adolescents and young adults, and is characterized by hepatobiliary, neurologic, psychiatric and ophthalmologic manifestations. Mechanism of status dystonicus in WD is not clear. We present here a case study of Wilson’s disease in a 14-year-old child with dystonia not responded with routine therapy.
cardiovascular, respiratory or gastrointestinal system. On examination his B.P was 130/80 mm Hg, Pulse rate was 90/min. Investigations: Haematological investigation revealed, Haemoglobin % - 18%, Albumin: 3.0 g/dl, Serum Creatinine: 1.2 mg/dl, UREA (B): 29 mg/dl, Alanine Transaminase: 104 IU, Aspartate Aminotransferase: 65 IU, Alkaline phosphatase: 142 IU/lit, Serum ceruloplasmin: 374 mg/lit, Copper: 59 µmol/dl. Slit Lamp Examination- KAYSER FLEISHER RING is present, After confirming diagnosis patient was started on Trientein hydrochloride 300 mg three times a day (TDS), Benzhexol 2 mg four times in a day (QDS) gabapentin 80mg(ODS). Follow up is being taken regularly for next six months. Patient is gradually improving and still continuing treatment.

D-penicillamine-induced aggravation of dystonia is known in patients with Wilson disease.6,7,8 Similar aggravation of dystonia is also known with Trientine and zinc monotherapies; the condition is however more severe with D-penicillamine. D-penicillamine does not produce dystonia when used in other disorders, like rheumatoid arthritis, copper sulfate or arsenic poisoning. Underlying mechanism of D-penicillamine-induced status dystonicus in WD is not clear. Increased copper turnover secondary to copper chelation, resulting in injury to basal ganglia, thalamus and brainstem is a likely possibility. The signal changes in thalamus and brainstem observed on MRI during D-penicillamine-induced increase in dystonia may reverse back to normal on discontinuation of D-penicillamine.8

D-penicillamine-induced status dystonicus responds poorly to anti-dystonia drugs. Our patient responded well to gabapentin after failing to respond to other anti-dystonia drugs. Gabapentin can improve limb dystonia, hemifacial spasms, hemichorea/hemiballismus and torticollis.10,11,12 Interestingly, gabapentin evoked good response in patients with familial paroxysmal nonkinesogenic dyskinesia.12 In our patient, gabapentin improved paroxysmal dystonic spells more than the sustained dystonia. Mechanism of action of gabapentin in paroxysmal dyskinesia and paroxysmal dystonic spells is not known. Gabapentin inhibits K1-evoked Ca21 increases in neocortical synaptosomes via inhibition of voltage-dependent calcium channels (VD-CCs) and reduces K1-evoked glutamate release from neocortical and hippocampal slices.13,14 It also inhibits excitatory neurotransmitter release in the dorsal horn of cord dorsal . These actions of gabapentin are hypothesized due to its selective agonist activity at neuronal GABA  receptors, which are coupled to VD-CCs.11 Possibly, these mechanisms make gabapentin effective against other paroxysmal disorders like migraine, epilepsy, trigeminal neuralgia, neuromyotonia. These mechanisms can also be hypothesized for the response evoked in our patients of paroxysmal dystonic spells. Patients with WD may have associated clinically overt or subclinical hepatopathy. Since gabapentin has renal route of clearance, its use is safe in these patients.

**Conclusion:** Status dystonicus with paroxysmal dystonic spells is a rare but serious complication of D-penicillamine therapy in patients with WD. Underlying mechanism of this condition is not known. Gabapentin can be used to control D-penicillamine-induced paroxysmal dystonic spells in patients with WD.
REFERENCES